Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Page 1 of 4 – Personal Details ONLINE REGISTRATION Before you start your registration, please note: You need to complete all steps at once to...

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the role of neoadjuvant immunotherapy in...

Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the rationale and results from two arms...

Page 1 of 4 – Personal Details ONLINE REGISTRATION Before you start your registration, please note: You need to complete all steps at once to...

In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell...

The Post-ASH 2022 Multiple Myeloma Highlights Virtual Workshop will feature a series of short presentations on multiple myeloma from invited experts on selected abstracts...

Registration - 1 week

Mashup Score:3

The 2023 Tandem Meetings will feature both in-person and virtual programing to allow you to choose the experience that best fits your schedule, budget and needs....

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the...

Dan Vogl, MD, University of Pennsylvania, Philadelphia, PA, shares some results from the Phase I/II first-in-human study of modakafusp...

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results of a study analyzing the prognostic value of...

  • 1615741831467204608 Profile photo of Madelyn

    🎥 @BrunoPaiva_UNAV shares some insights into the impact of sustained undetectable MRD on the survival of patients with multiple myeloma treated with ide-cel in the KarMMa trial: 👉https://t.co/EqHPISEco7👈 #MMsm #HemOnc #ImmunoOnc #mmMRD #CARTcell #tcellrx - view on twitter